top of page




The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Read more

Mus LMLambertz IClaeys SKumps CVan Loocke WVan Neste CUmapathy GVaapil MBartenhagen CLaureys GDe Wever OBexell DFischer MHallberg BSchulte JDe Wilde BDurinck KDenecker GDe Preter KSpeleman F1.             

Sci Rep. 2020 Jan 14;10(1):218


Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. Read more

Cervantes-Madrid DSzydzik JLind DEBorenäs MBemark MCui JPalmer RHHallberg B.             

Sci Rep. 2019 Dec 18;9(1):19353

Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements. Read more

Javanmardi NFransson SDjos A1, Umapathy GÖstensson MMilosevic JBorenäs MHallberg BKogner PMartinsson 1, Palmer RH               

Genes Chromosomes Cancer. 2019 Jul 2

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. Read more

Alam MWBorenäs MLind DE, Cervantes-Madrid DUmapathy GPalmer RHHallberg B.              

Front Oncol. 2019 Jul 5;9:579


Targeting anaplastic lymphoma kinase in neuroblastoma, review. Read more

Umapathy GMendoza-Garcia PHallberg BPalmer RH.               

APMIS. 2019 May;127(5):288-302.


Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. Read more

Van den Eynden JUmapathy GAshouri ACervantes-Madrid DSzydzik JRuuth KKoster JLarsson E, Guan JPalmer RH, Hallberg B               Sci Signal. 2018 Nov 20;11(557).

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib Read more

Guan JFransson S, Siaw JTTreis DVan den Eynden J, Chand DUmapathy GRuuth KSvenberg PWessman SShamikh AJacobsson HGordon LStenman JSvensson PJHansson MLarsson EMartinsson T, Palmer RH, Kogner P Hallberg B.                                               

Cold Spring Harb Mol Case Stud. 2018 Aug.


MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Read more
Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Science Signaling.


Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation. Read more
Guan J, Yamazaki Y, Chand D, van Dijk JR, Ruuth K, Palmer RH, Hallberg B.

MDPI Cancers. 


Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent. Read more


Jikui Guan, Georg Wolfstetter....,,,,,,,,Ruth H Palmer, Bengt Hallberg. 




The role of the ALK receptor in cancer biology. Read more

 Bengt Hallberg and Ruth H Palmer. Ann Oncol (2016) 27.


The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Read more

Jikui Guan.., Damini Chand........., Ganesh Umapathy, Ruth H Palmer, Bengt Hallberg. 
Dis Model Mech.


Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Read more

Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B. Oncotarget.





FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma Kinase. Read more


Jikui Guan, Ganesh Umapathy, Yasuo Yamazaki, Georg Wolfstetter, Patricia Mendoza,Kathrin Pfeifer, Ateequrrahman Mohammed, Fredrik

 Hugosson, Hongbing Zhang, Amy W Hsu, Robert Halenbeck, Bengt Hallberg, Ruth H Palmer. ELIFE SCIENCES.


Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism. Read more


Barbara Witek ,Abeer El Wakil ,Christoffer Nord,Ulf Ahlgren,Maria Eriksson,Emma Vernersson-Lindahl,Åslaug Helland,Oleg A. Alexeyev,Bengt Hallberg ,Ruth H. Palmer. PLOS ONE. 





The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in

neuroblastoma. Read more.


Ganesh Umapathy, Abeer El Wakil2, Barbara Witek,, Louis Chesler, Laura Danielson, Xianming Deng, Nathanael S. Gray, Mikael Johansson, Samuel Kvarnbrink, Kristina Ruuth, Christina Schönherr, Ruth H. Palmer, and Bengt Hallberg. SCIENCE SIGNALING



Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Read more.


Bengt Hallberg & Ruth H. Palmer. Nature Reviews.



Publication list, BH complete.


Articles produced during Ph.D years.


  1. Hallberg, B., and Grundström, T. Tissue specific sequence motif in the enhancer of the mouse retrovirus SL3-3. Nucleic Acid Research, 16, 5927-5944, 1988.

  2. Thornell, A., Hallberg, B., and Grundström, T. Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3. Molecular Cell Biology, 8, 1625-1637, 1988.

  3. Nilsson, P., Hallberg, B., Thornell, A., and Grundström, T. (1989). Interaction of NF I with the SL3-3 virus enhancer: mutant analysis of the binding site. Nucleic Acid Research, 17, 4061-4075.

  4. Thornell, A., Hallberg, B., and Grundström, T. Binding of SL3-3 Enhancer Factor 1 transcriptional activator to viral and chromosomal sequences. Journal of Virology, 65, 42-50, 1991.

  5. Hallberg, B., Pedersen, F.S., Schmidt, P., Lutz, P., and Grundström, T. SEF1 transcriptional activators are required for tumour formation by SL3-3 murine leukemia virus.  Journal of Virology, 65, 4177-4181, 1991.

  6. Corneliussen, B., Thornell, A., Hallberg, B., and Grundström, T. Helix-loop-helix transcriptional activator proteins bind to a sequence in the    glucocorticoid response element of the retrovirus enhancers. Journal of Virology, 65, 16084-16093, 1991.                                    

   7.Hallberg, B., Thornell, A., Holm, M., and Grundström, T. SEF1 binidng sites is important for T cell specific enhancers of genes for T cell       receptor CD3 subunits. Nucleic Acid Research, 20, 6495-6499, 1992.


Articles published during post-doc period and thereafter.


  1. Hallberg, B., Rayter, S., and Downward, J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. Journal of Biological Chemistry, 269, 3913-3916, 1994.                                             

  2. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., Parker, P.J. The activation of phosphatidylinositol 3-kinase by ras. Current Biology, 4, 798-805, 1994.

  3. Corneliussen, B., Holm, M., Waltersson, Y., Onions, J., Hallberg, B., Thornell, A., and Grundström, T. Calcium/Calmodulin inhibition of basic-helix-loop-helix transcription factor domains. Nature, 368, 760-764, 1994.

  4.  Khwaja, A., Hallberg, B., Warne, P., and Downward, J. Network of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins.  Oncogene, 12, 2491-2498, 1996.

  5. Ethelberg, S., Hallberg, B., Lovmand, J., Schmidt, J., Luz, A., Grundström, T., and Pedersen, F.S. Second site proviral alterations in lymphomas induced by enhancer core mutants of SL3-3 Murine Leukemia virus: Negative effect of Nuclear factor 1 binding site. Journal of Virology, 71, 1196-1206, 1997.

  6. Hallberg, B., Ashcroft, M., Kaplan, D., and Downward, J. Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc, but does not involve phosphoinositide 3-OH kinase. Oncogene, 17, 691-698, 1998.

  7. Ashcroft, M., Stephens, R.M., Hallberg, B., Downward, J., and Kaplan, D.R.                     The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth.                                       Oncogene, 18, 4586-4597, 1999.

  8. Henriksson. M.L., Rosqvist.R., Telepnev.M., Wolf-Watz.H., and Hallberg.B.  Ras and MAP kinase activation by EGF is inhibited by ExoS ADP-ribosylation of Ras.        Biochemical Journal, 347, 217-222, 2000.

  9. Henriksson, M.L, Trollér, U., and Hallberg. B. (2000). 14-3-3 proteins are required for inhibition of Ras by Exoenzyme S. Biochemical Journal, 349, 697-701, 2000.                                          

  10. Dukazymuremyi. J-M., Rosqvist. R., Hallberg. B., Åkerström. B., Wolf-Watz. H., Schesser. K. The Yersinia protein kinase A is a host-factor inducible RhoA/Rac-binding virulence factor. Journal of Biological Chemistry, 275, 35281-35290, 2000.                                                                                          

  11. Edsjö. A., Hallberg. B., Fagerström. S., Larsson. C, Axelsson. H., and Påhlman. S.             NT3 stimulated TrkC-transfected neuroblastoma cells differetiate  into a less mature phenotype than corresponding NGF treated TrkA transfected cells. Cell Growth Differ.12(1):39-50, 2001. 

  12. Sundin. C., Henriksson, M.L., Hallberg, B., Forsberg, Å., and Frithz-Lindsten, E. Exoenzyme T of P. aeruginosa elicits cytotoxicity without interfering with Ras signal transduction. Cellular Microbiology, 3(4):237-246, 2001.                                                                                                    

  13. Ruuth. K,. Carlsson. L., Hallberg. B., and Lundgren. E. (2001). IFN-alpha activates the PI-3-kinase/PKB/Akt pathway in human primary B-lymphocytes.    Biochem Biophys Res Commun. 284(3):583-6, 2001.                            

  14. Nilsson, J., Vallbo. C., Guo. D., Golovleva. I., Hallberg. B., Henriksson. R., Hedman. H. Cloning, characterization, and Expression of human LIG1. Biochem Biophys Res Commun. 284(5):1155-61, 2001.

  15.   Paruchuri. S., Hallberg. B., Juhas. M., Larsson. C., Sjölander. A.                Leukotriene D4 enhances proliferation of intestinal epithelial cells through a ras-independent mitogen-activated protein kinase pathway. Journal of Cell Science, 115, 1883-1893, 2002.

  16. Lindholm. C.K., Henriksson. M.L., Hallberg. B., Welsh. M. (2002). Shb links SLP-76 and Vav with the CD3 complex, in Jurkat T cells. European J of Biochemistry, 269, 3239-3288, 2002.                             

  17. Henriksson, M.L., Sundin, C., Jansson A., Forsberg Å., Palmer R.H., and Hallberg B. (2002) Exoenzyme S shows selective ADP-ribosylation and GAP activities towards small GTPases in vivo. Biochemical Journal 367(3): 617-628, 2002.

  18. Henriksson, M.L., Francis M.S., Peden A., Stefansson K., Palmer R.H., Aitken, A., and Hallberg B. Identification of a non-phosphorylated 14-3-3 binding motif on Exoenzyme S in vivo. European J of Biochemistry, 269(20):4921-4929, 2002.

  19. Aila M, Telpnev M, Hallberg B, Wolf-Watz H, and Rosqvist R. In vitro GAP acitivity towards RhoA, Rac1 and Cdc42 is not a prerequisite for YopE induced HeLa cell cytotoxicity. Microbial Pathogenesis 2003;34(6):297-308 . 

  20. Hallberg, B., (2002)."Exoenzyme S binds its co-factor 14-3-3 through a non-phosphorylated motif". Biochem Soc Trans. 30(4):401-5, 2002.

  21. Ekstand, J.A., Cao R, Nyström S, Björndahl M, Fluur C, Jönsson-Rylander A-C, Hassani H, Hallberg B, Nordlander M, Cao Y. Deletion of NY2 recetpor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6033-8.

  22. Lorén, C., Englund, C. Grabbe, C.,  Hallberg, B., Hunter. T., Palmer. RH.                           A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster . EMBO reports, Aug;4(8):781-6, 2003.

  23.  Englund, C., Lorén. C., Grabbe, C., Varshney. G., Deleuil, F., Hallberg. B., and Palmer, R.H. Jeb signals via the DAlk receptor tyrosine kinase to drive visceral muscle fusion.  Nature Vol 425 No 6957 pp450-454, 2003.

  24. Wandzioch, E., Edling, C.,Palmer, R.H., Carlsson, L., and Hallberg, B.                           A critical role for phosphoinositide 3-kinase in the activation of Forkhead, MEK and mitogen-activated protein kinases by Steel Factor in hematopoietic precursor cell lines.  Blood. 104(1):51-7, 2004.

  25. Sundin, C., Hallberg, B., Forsberg, Å. ADP-ribosylation by Exoenzyme T of Pseudomonas aeruginosa induces an irreversible effect on the host cell cytoskeleton in vivo. FEMS Microbiol Lett., 1;234(1):87-91, 2004.                                                      

  26. Yasmin, L., Jansson, .L., Downward, J., Warne, P., Palmer, R.H., and Hallberg, B.,  Activated Ras, and PKB protect cells upon infection by bacteria expressing type III secretion/translocated Exoenzyme S. Cellular Microbiology, 8(5):815-22, 2006.

  27.  Vernersson. E., Khoo, N., Henriksson, M.L., Roos, G., Palmer, R.H., Hallberg, B.                Characterization of the expression of the ALK Receptor Tyrosine Kinase in mice. Gene Expression Patterns. doi:10.1016/j.modgep.2005.11.006

  28. Yasmin, L., Jansson, A.L., Panahandeh, T., Palmer, R.H., Francis, M.S., Hallberg, B. Delineation of Exoenzyme S residues that mediate the interaction with 14-3-3 and its biological activity. FEBS J. 273(3):638-46, 2006.

  29. Aili. M., Hallberg. B., Wolf-Watz.. H and Rosqvist. R. Identification of virulent yopE mutants of Yersinia pseudotuberculosis lacking in vivo GAP activity towards Rho, Rac1 and Cdc42. Cellular Microbiology. 8(6):1020-33, 2006.

  30. Charlotte E. Edling, Malin Pedersen, Leif Carlsson, Lars Rönnstrand, Ruth H. Palmer and Bengt Hallberg.  Hematopoietic progenitor cells utilize conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. British Journal of Haematology 136 (2), 260–26, 2007

  31. Yang, H-L., Eriksson, T., Vernersson, E., Vigny, M, Hallberg, B* and Palmer, R.H*. The ligand Jelly Belly (JEB) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.    (* co-last-author)                                                                       J Exp Zoolog B Mol Dev Evol. 2007 May 15;308(3):269-82

  32. Ottman, C., Yasmin, L., Weyand, M., Veesenmeyer, J.L., Diaz, M.H., Palmer, R.H., Francis, M.S., Hauser, A.R., Wittinghofer, A., and Hallberg, B. Phosphorylation independent interaction between 14-3-3-Exoenzyme S: from structure to pathogenesis. EMBO J. 2007 Feb 7;26(3):902-13                                                                                                        

  33. Köhn. L., Kadzhaev, K., Burstedt, M.I.S., Haraldsson, S., Hallberg, B., Sandgren, O., and Golovleva, I. Mutation in the PYK2-binding domain of PITPNM3 causes autosomal dominant cone dystrophy (CORD5) in two Swedish families. Eur J Hum Genet. 2007 Jun;15(6):664-71.                                                                                         

  34. Sitaram, RT., Cairney, JC., Grabowski, P., Keith, WN., Hallberg, B., Ljungberg, B., Roos, G. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma.  Int J Cancer. 2009 Aug 15;125(4):783-90.

  35. Schönherr, C., Yang, H-L., Vigny, M., Palmer, RH., and Hallberg, B.                Anaplastic Lymphoma Kinase (ALK) activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. Oncogene,  2010 May 13;29(19):2817-30.

  36. Yasmin, L, Veesenmeyer, JL., Diaz, MH., Francis, MS, Palmer, RH., Hauser, RH and Hallberg, B. Electrostatic interactions play a minor role in the binding of ExoS to 14-3-3.        Biochem J. 2010 29;427(2):217-24.

  37. Martinsson, T., Eriksson. T., Abrahamsson, J., Careén, H., Hansson, M., Kogner, P., Kamraj, S., Schönherr, C., Weinmar, J., Ruuth, K., Palmer. R.H., and Hallberg, B. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.Cancer Research, 2011 71;1, 98-105.

  38. P.Mazot, I.Janoueix-Lerosey, MC.Boutterin, A. Figueiredo, A.Cazes, V.Raynal, V.Combaret, B.Hallberg, R.H.Palmer, O.Delattre and M.Vigny. The constitutive activity of the mutated form of ALK F1174X impairs receptor trafficking. Oncogene, 2011 Apr 28;30(17):2017-25, 2011.                       

  39. Schönherr, C., Eriksson, T.,Ruuth,T.,Yamazaki, Y.,Ottmann, C., Combaret, V., Vigny, M., Kamaraj, S., Palmer, R.H.#, and Hallberg, B#. The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro or in vivo. Translational Oncology, 2011, 4: 4, 249-255.

  40. Schönherr. C., Ruuth. K., Yamazaki. Y., Eriksson. T., Christensen. J., Palmer R.H*., and Hallberg. B*. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and TAE684. Biochemical Journal, 2011, Aug 15, Epub ahead of print                                                                                              

  41. Schönherr. C., Ruuth. K., Kamaraj. S., Combaret. V.,Wang, C-L., Yang, H-L., Djos, A., Martinsson, T., Christensen. J., Palmer R.H., and Hallberg.  ALK regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene, 2012 Jan 30. doi: 10.1038/onc.2012.12. [Epub ahead of print]

  42. Mazot, P., Cazes, a., Dingli, F., Degoutin, J., Irinopoulou, T., Boutterin, MC., Lombard, B., Loew, D., Hallberg, B., Palmer, RH., Delattre, O., Janoueix-Lerosey and Vigny, M.

  43. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment. PLOS One 2012;7(3):e33581. Epub 2012 Mar 30.

  44. Berry, T., Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma.  Cancer Cell. 2012 Jul 10;22(1):117-30.                                                          

  45. Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer R, Hallberg B. Cell and Drosophila model systems define three classes of ALK mutations in neuroblastoma. Dis Model Mech. 2013 Mar;6(2):373-82. Epub 2012 Oct 25.

  46. Yamazaki Y, Schönherr C, Varshney GK, Dogru M, Hallberg B, Palmer RH.        Goliath family E3 ligases regulate the recycling endosome pathway via VAMP3 ubiquitylation. EMBO J. 2013 Feb 20;32(4):524-37.

  47. Velghe AI, Van Cauwenberghe S, Polyansky AA, Chand D, Montano-Almendras CP, Charni S, Hallberg B, Essaghir A, Demoulin JB. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.        Oncogene,  Volume: 33   Issue: 20   Pages: 2568-25762013 Jun 10. doi: 10.1038/onc.2013.218. [Epub ahead of print].

  48. Popichenko D, Hugosson F, Sjögren C, Dogru M, Yamazaki Y, Wolfstetter G, Schönherr C, Fallah M, Hallberg B, Nguyen H, Palmer RH. Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm. Development. 2013 Aug;140(15):3156-66. doi: 10.1242/dev.094466. Epub 2013 Jul 3.                                           

  49. Sattu, K, Hochgräfe, F, Wu, J, Umapathy, G, Schönherr, C, Ruuth, K., Chand,  D., Witek, B., Fuchs, J., Li, T., Hugosson, F., Daly, R.J., Palmer, R.H., and Hallberg B. Phosphoproteomic analysis of ALK downstream signaling pathways identifies STAT3 as a functional target of activated ALK in neuroblastoma cells. FEBS J. Volume: 280   Issue: 21   Special Issue: SI   Pages: 5269-5282   Published: NOV 2013  2013 Jul 27. doi: 10.1111/febs.12453. [Epub ahead of print].

  50. Fransson S., Hansson, M., Ruuth, K., Djos, A., Berbegall, A., Javanmardi, N., Abrahamsson, J., Palmer, R.H., Noguera, R., Hallberg, B., Kogner, P., and Martinsson, T.  Intragenic Anaplastic Lymphoma Kinase (ALK) earrangements; Translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223.

  51. Umapathy G., El Wakil, A., Witek B.,Chesler, L., Danielson, L., Deng, X., Gray, N.s., Johansson, M. Kvarnbrink, S., Ruuth, K., Schönherr, C., Palmer, R.H., Hallberg, B.          A critical role for ERK5 in the regulation of MYCN expression by ALK in neuroblastoma             Science Signaling. 2014 Oct 28;7(349):ra102. doi: 10.1126/scisignal.2005470.

  52. Witek, B, El Wakil, A., Nord, C., Ahlgren, U., Eriksson, M., Vernersson, E., Helland, Å., Alexeyev, O.A., Hallberg, B*. and Palmer, R.H*. Targeted disruption of ALK reveals a potential role in hypogonadotropic hypogonadism.        PLoS One. 2015 May 8;10(5):e0123542. doi: 10.1371/journal.pone.0123542..

  53. Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH.                       FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma Kinase.              Elife. 2015 Sep 29;4. doi: 10.7554/eLife.09811.

  54. Arts,F.A.,Chand, D., Pecquet,C., Velghe, A I., Constantinescu,S., Hallberg, B., and J-B Demoulin. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene, October 12, 2015; doi:10.1038/onc.2015.383

  55. Siaw, T.J., Wan, H., Pfeifer, K., Rivera, R.M., Palmer, R.H. and Hallberg, B.  Brigatinib, an Anaplastic Lymphoma Kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17;7(20):29011-29022. doi: 10.18632/oncotarget.8508.

  56. Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B. Dis Model Mech. 2016 Jul 7. pii: dmm.024448. [Epub ahead of print]

  57. Guan J., Wolfstetter, G., Siaw. J., Chand D, Hugosson, F., Palmer RH, and Hallberg B. ALK L1198F and G1201E mutations identified in anaplastic thyroid cancer pateints are not ligand-independent. Oncotarget. 2016 Dec 24. doi: 10.18632/oncotarget.14141.

  58. Umapathy, G., Gustafsson, D.E., Javanmardi, N., Cervantes-Madrid, D., Djoos, A., Martinsson, T., Palmer, R.H., and Hallberg, B. ALK addictive neruoblastoma cell lines are associated with growth upon treatment with MEK inhibitor tramatinib. Science Signaling, accepted for publication, June 2017.




Review articles, editorials and others


  1. Pedersen FS, Paludan K, Dai HY, Duch M, Jorgensen P, Kjeldgaard NO, Hallberg B, Grundstrom T, Schmidt J, Luz A. The murine leukemia virus LTR in oncogenesis: effect of point mutations and chromosomal integration site. Radiat Environ Biophys. 1991;30(3):195-7

  2. Aili M, Hallberg B, Wolf-Watz H, Rosqvist . GAP activity of Yersinia YopE. Methods Enzymol 2002;358:359-70.                                                                                    

  3. Edling, C., and Hallberg, B. c-Kit – an essential hematopoietic cell receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39(11):1995-8.

  4. Palmer, RH., Vernersson, E., Grabbe, C., Hallberg, B. Anaplastic lymphoma kinase; in disease and signalling. Biochem J. 2009 May 27;420(3):345-61.

  5. Hallberg, B., and Palmer, R.H.            Editorials: Crizotinib-Latest champion in the cancer wars? The New England Journal of Medicine, 2010, 363;18 1760-1762

  6. Hallberg, B and Palmer, RH. ALK and NSCLC: Targeted therapy with ALK inhibitors F1000 Medicine Reports 2011, 3:21 (doi:10.3410/M3-2 )

  7. Christina Schönherr, Bengt Hallberg* and Ruth H. Palmer*. Anaplastic Lymphoma Kinase in human cancer. Critical Reviews in Oncogenesis, 2012;17(2):123-43.                                                      

  8. Palmer, R.H., Johansson, M., Hallberg, B. ALK inblandad i många cancerformer. (Swedish review article). Oncologi i Sverige, Vol.2:2012.                                                          

  9. Hallberg, B. and Palmer RH. Mechanistic insight into anaplastic lymphoma kinase (ALK) receptor tyrosine kinase in human cancer biology. Nature Review Cancer, Vol 13, 685-700, 2013.                                                                                                                                                   

  10. Johansson, M., Chand, D., Umapathy, G., Palmer, R.H., Hallberg, B. ALK vERKar på MYCN. Onkologi i Sverige, Vol. 1:2015.

  11. Palmer, R.H. and Hallberg B. Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase family (The Receptor Tyrosine Kinase handbook) The ALK Receptor Family Publisher; Springer Science. Editors, Drs., Deric Wheeler and Y Yarden.2015, DOI 10.1007/978-3-319-11888-8

  12. B. Hallberg & R. H. Palmer. The role of the ALK receptor in cancer biology. Ann Oncol (2016) 27 (suppl 3): iii4-iii15 doi:10.1093/annonc/mdw301








































bottom of page